Abstract: The invention relates to a kit of parts, consisting of compositions (C1) and (C2) in separate containers, for use in the treatment or prevention of osteoarthritis in a vertebrate, wherein: (a) composition (C1) is a liquid hydrogel formulation comprising a polymer gellant with chemically cross-linkable groups; (b) composition (C2) is an aqueous auxiliary formulation comprising either one or more dissolved cross-linkers Z having two or more reactive groups that can chemically cross-link the polymer gellant by forming covalent bonds; or comprising one or more dissolved compounds Y, selected from the group consisting of oxidant, oxidase, peroxidase and combinations thereof, that initiate or mediate chemical cross-linking of the polymer gellant; wherein said treatment comprises combining compositions (C1) and (C2) to form a liquid hydrogel composition (C3) and administering said liquid hydrogel composition (C3) to the synovial fluid or to the cavity of a synovial joint of the vertebrate, to form a cross-linked hyd

Abstract: A method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s) is described. Related uses, and compositions, products and kits for the same are further described.

Abstract: The invention relates to a method of diagnosing or screening for 27-hydroxylase (CYP27A1) deficiency in an animal comprising: determining in a biological sample the intensity signal by mass analysis of at least a bile alcohol glucuronide and a C24- or C27-bile acid or a conjugate thereof, comparing the intensity signals to a control sample or control value, and determining 27-hydroxylase (CYP27A1) deficiency based on said comparison.

Abstract: The use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

Abstract: The present application relates to an assembly for a joint (1, 2, 3, 4), the joint comprising a joint implant (5, 6) between a proximal segment of a limb that is proximal to the joint and a distal segment of the limb that is distal to the joint and in which the joint is configured to allow rotation of the proximal and distal segments with respect to one another about an axis that intersects a first plane, and to inhibit rotation in the second and third plane, both perpendicular to the first plane, the assembly being for subjecting the joint at predetermined angles of the joint rotation in the second and third plane to a defined bending moment to induce a load to the implant that causes a movement of the implant in relation to the bone of the proximal or distal segments.

Abstract: The invention relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus, the Env polypeptide comprising at least the amino acid residues K275, D276 and R278, wherein said numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.

Abstract: The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Abstract: A method of killing bacteria and an antibiotic kit are provided herein. The method includes treating the bacteria with a DNA condensation-inducing compound; and subsequently treating the bacteria with an Eis inhibitor. The kit includes a DNA condensation-inducing compound packaged together with an Eis inhibitor.

Abstract: The present disclosure is directed toward low-coherence interferometry imaging systems comprising a common-path interferometer that is at least partially integrated as part of a planar lightwave circuit is disclosed. Imaging systems in accordance with the present disclosure are implemented in integrated optics without the inclusion of highly wavelength-sensitive components. As a result, they exhibit less wavelength dependence than PLC-based interferometers of the prior art. Further, common-path interferometer arrangements in accordance with the present disclosure avoid polarization and wavelength dispersion effects that plague prior-art PLC-based interferometers. Still further, an integrated common-path interferometer is smaller and less complex than other integrated interferometers, which makes it possible to integrate multiple interferometers on a single chip, thereby enabling multi-signal systems, such as plane-wave parallel OCT systems.

Abstract: The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Abstract: A high-resolution single-chip spectrometer is disclosed. Embodiments of the present invention are analogous to Fourier-transform spectrometers; however, embodiments of the present invention have no moving parts. An illustrative embodiment is a spectrometer having a nested plurality of Mach-Zehnder interferometers (MZIs), where all MZIs share at least one surface-waveguide section in each of its sample and reference arms. The light signals in the sample and reference arms are tapped at a series of discrete locations along their length via electro-optically-controlled directional couplers, which are separated by uniform-length waveguide portions in each arm, but where the uniform lengths are different in the sample and reference arms providing a different path-length difference for the arms of each MZI. The tapped light from the sample and reference arms is recombined at a low-loss beam combiner to generate a distribution of optical power as a function of time-delay difference in the arms.

Abstract: A high-performance single-chip, integrated-optics-based OCT system is disclosed, where the length of the reference arm is digitally variable. The reference arm includes a plurality of switch stages comprising a 2×2 tunable wavelength-independent waveguide switch that can direct an input light signal onto either of two different-length output waveguides. In some embodiments, the directional couplers are thermo-optic based. Some embodiments include a solid-state scanning system for scanning a sample signal along a line of object points on the sample under test.

Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

Abstract: The present invention provides a method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s). The invention also provides related uses, and compositions, products and kits for the same.

Abstract: A low coherence interferometry imaging system comprising a common-path interferometer that is at least partially integrated as part of a planar lightwave circuit is disclosed. Imaging systems in accordance with the present invention are implemented in integrated optics without the inclusion of highly wavelength-sensitive components. As a result, they exhibit less wavelength dependence than PLC-based interferometers of the prior art. Further, the common-path interferometer arrangement of the present invention avoids polarization and wavelength dispersion effects that plague prior-art PLC-based interferometers. Still further, an integrated common-path interferometer is smaller and less complex than other integrated interferometers, which makes it possible to integrate multiple interferometers on a single chip, thereby enabling multi-signal systems, such as plane-wave parallel OCT systems.

Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration.

Abstract: The invention relates to an NK3 agonist or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a atrial arrhythmia. The invention further relates to a composition comprising an NK3 agonist for use in the treatment of a patient suffering from a disease wherein the electrical activity of an atrial heart cell is affected.

Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.

Abstract: The present invention relates to antibody which binds to an epitope located within the BMPR1 binding region of BMP4.

Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.